D
David A. Mankoff
Researcher at University of Pennsylvania
Publications - 391
Citations - 18097
David A. Mankoff is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 73, co-authored 367 publications receiving 16229 citations. Previous affiliations of David A. Mankoff include University of Washington Medical Center & Seattle Cancer Care Alliance.
Papers
More filters
Journal Article
Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials
Lalitha K. Shankar,John M. Hoffman,Steve Bacharach,Michael M. Graham,Joel S. Karp,Adriaan A. Lammertsma,Steven M. Larson,David A. Mankoff,Barry A. Siegel,Annick D. Van den Abbeele,Jeffrey T. Yap,Daniel C. Sullivan +11 more
TL;DR: This paper presents a meta-modelling study of the response of positron emission tomography (PET) to radiolysis (radiolysis) and its applications to nuclear medicine and Radiology.
Journal ArticleDOI
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Gary J. Kelloff,John M. Hoffman,Bruce E. Johnson,Howard I. Scher,Barry A. Siegel,Edward Y. Cheng,Bruce D. Cheson,Joyce O'Shaughnessy,Kathryn Z. Guyton,David A. Mankoff,Lalitha K. Shankar,Steven M. Larson,Caroline C. Sigman,Richard L. Schilsky,Daniel C. Sullivan +14 more
TL;DR: Its potential to facilitate drug development in seven oncologic settings (lung, lymphoma, breast, prostate, sarcoma, colorectal, and ovary) is addressed and its potential as a surrogate of clinical benefit is addressed.
Journal ArticleDOI
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Laurie L. Carr,David A. Mankoff,Bernardo H. L. Goulart,Keith D. Eaton,Peter T. Capell,Elizabeth M. Kell,Julie E. Bauman,Renato G. Martins +7 more
TL;DR: Continuous administration of sunitinib was effective in patients with iodine-refractory WDTC and MTC, and differences between response categories were statistically significant (P = 0.03).
Journal ArticleDOI
Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.
Joseph G. Rajendran,David A. Mankoff,Finbarr O'Sullivan,Lanell M. Peterson,David L. Schwartz,Ernest U. Conrad,Alexander M. Spence,Mark Muzi,D. Gregory Farwell,Kenneth A. Krohn +9 more
TL;DR: Hypoxia is a general factor affecting glucose metabolism; however, some hypoxic tumors can have modest glucose metabolism, whereas some highly metabolic tumors are not hypoxic, showing discordance in tracer uptake that can be tumor type specific.
Journal ArticleDOI
Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer
Hannah M. Linden,Svetlana Stekhova,Jeanne M. Link,Julie R. Gralow,Robert B. Livingston,Georgiana K. Ellis,Philip H. Petra,Lanell M. Peterson,Erin K. Schubert,Lisa K. Dunnwald,Kenneth A. Krohn,David A. Mankoff +11 more
TL;DR: Quantitative FES-PET can predict response to hormonal therapy and may help guide treatment selection, and a multi-institutional collaborative trial would permit definitive assessment of the value of Fes-PET for therapeutic decision making.